A plasmacytoma is a tumor made of plasma cells, the white blood cells responsible for producing antibodies, that grows as a single mass rather than spreading diffusely through the bone marrow the way multiple myeloma does. The condition comes in two main forms: solitary bone plasmacytoma, which develops within a bone, and solitary extramedullary plasmacytoma, which arises in soft tissue outside the bone marrow. That distinction matters because the two behave differently, respond to treatment differently, and carry very different odds of eventually becoming myeloma.
Two Types, Two Trajectories
Solitary bone plasmacytoma (SBP) accounts for the majority of cases. It tends to appear in the spine, pelvis, or ribs, and patients are typically somewhat younger than those diagnosed with the extramedullary form. Solitary extramedullary plasmacytoma (SEP) most often shows up in the head and neck region, especially the nasal cavity and sinuses. Males outnumber females in both forms, though the gender imbalance is more pronounced in SEP.
The prognosis gap between these two types is significant. Roughly 70% of patients with SEP remain disease-free at ten years, a figure that SBP cannot match because bone plasmacytomas carry a substantially higher risk of evolving into full-blown multiple myeloma.1PubMed. Solitary bone plasmacytoma and extramedullary plasmacytoma One large systematic review of head and neck extramedullary plasmacytomas found five-year and ten-year overall survival rates of about 78% and 69%, respectively, with ten-year local control exceeding 88%.2PubMed. Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases For bone plasmacytomas treated with radiation, a long-term outcomes study found a ten-year myeloma-free survival rate of only about 24% for SBP, compared with 87% for SEP.3PubMed Central. Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma
How It Is Diagnosed
Diagnosis rests on proving that a single site contains a clonal mass of plasma cells and that the patient does not already have multiple myeloma. That requires a tissue biopsy, typically stained for markers like CD138 to confirm the cells are plasma-cell derived, along with blood work looking for abnormal proteins and a bone marrow biopsy to rule out widespread disease.4PubMed. Solitary bone plasmacytoma and extramedullary plasmacytoma Imaging is essential to confirm that no other lesions exist elsewhere. A comparative study found that whole-body MRI detected about 98% of plasmacytomas versus roughly 84% for PET/CT, a statistically meaningful difference suggesting MRI may be the more sensitive tool for initial staging.5PubMed Central. Whole-body MRI Versus [18F]FDG PET/CT in Diagnosing and Monitoring Plasmacytomas: A Comparative Study
There is also a growing role for laboratory tests that look deeper than standard screening. Elevated light-chain levels or an abnormal light-chain ratio in the blood can signal monoclonal protein activity even when the disease appears localized. In one reported case, elevated kappa light chains and an abnormal kappa-to-lambda ratio were present at initial diagnosis despite what appeared to be a single bone lesion, and the disease later progressed to widespread myeloma with multiple lytic lesions throughout the skeleton.6PubMed Central. Solitary Plasmacytoma and its Progression into Multiple Myeloma – A Case Report
Predicting Who Will Progress to Myeloma
The central worry with any plasmacytoma is that it will eventually turn into multiple myeloma. For bone plasmacytomas, that risk is uncomfortably high, and identifying which patients are most vulnerable is an active area of research.
One of the most powerful predictors involves using sensitive flow cytometry to examine bone marrow samples for tiny populations of clonal plasma cells that standard methods miss. In one study, about half of SBP patients had detectable clonal plasma cells in otherwise normal-looking marrow. Among those patients, roughly 71% progressed to myeloma, compared with only 8% of patients whose marrow tested negative, a dramatic separation.7PubMed. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma A separate study confirmed this pattern and found that combining flow-cytometry results with urinary light-chain testing could identify an excellent-outcome group (lacking both markers, with under 8% progression) and a high-risk group (with one or both markers, at 75% progression).8Blood. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis
A large multicenter study further refined this picture. Patients whose bone marrow showed any clonal involvement at diagnosis (classified as SBP with minimal marrow involvement) progressed to myeloma at a rate of about 92%, versus 76% for SBP without detectable marrow disease. The marrow-involved group had a median time to progression of just 15 months, with two-thirds progressing within two years. Certain genetic abnormalities in the tumor cells accelerated things further: patients with deletion of chromosome 17p had a 100% two-year progression rate.9PubMed Central. A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement
A population-based survival model that integrated factors like age, tumor location, and other clinical features found that low-risk patients had a median overall survival exceeding 12 years, while high-risk patients survived a median of under four years.10International Journal of General Medicine. Prognostic Nomogram for Predicting Overall Survival of Solitary Bone Plasmacytoma Patients: A Large Population-Based Study
Radiation as the Standard Treatment
Radiation therapy is the backbone of treatment for solitary plasmacytoma. Plasma cells are highly sensitive to radiation, and for a single tumor in one location, a focused course of radiation can achieve local control rates in the high 80% to 90% range. Guidelines from an international radiation oncology group recommend total doses of 35 to 40 Gy for smaller bone plasmacytomas (under 5 cm) and 40 to 50 Gy for larger ones or for extramedullary tumors.11International Journal of Radiation Oncology, Biology, Physics. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group Interestingly, at least one study found that lower doses (at or below 35 Gy) were not associated with a higher risk of local failure, suggesting the tumor’s radiosensitivity is fairly robust.12PubMed. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome
The ten-year local control rate after radiation has been reported at about 88%, with tumors larger than 5 cm being the ones most likely to recur locally.13PubMed Central. Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma Local control is excellent, but radiation alone does not prevent the disease from eventually appearing elsewhere in the body as myeloma, which is why adjuvant systemic therapy is an area of growing interest.
When Surgery Enters the Picture
Surgery is not the default treatment for most plasmacytomas, but certain situations demand it. Spinal plasmacytomas are the clearest example. Radiation controls the tumor cells effectively, but it does not rebuild a vertebral body that has already been weakened or collapsed. When a spinal plasmacytoma causes instability or compresses the spinal cord, surgical intervention may be needed to decompress neural structures and stabilize the spine.14PubMed Central. Surgical treatment of solitary plasmocytoma of the spine: case series One case report described a thoracic spine plasmacytoma causing cord compression at several vertebral levels, where surgical resection and reconstruction were performed because the Spinal Instability Neoplastic Score indicated potential spinal instability.15PubMed Central. Resection of Thoracic Plasmacytoma and Corpectomy Through the Anterolateral Thoracic Approach: A Case Report Reconstruction techniques for the cervical spine have included titanium plates and mesh cages filled with bone graft or cement.16Spine. Cervical Spine Solitary Plasmacytoma of Cervical Spine
For intracranial plasmacytomas, which are rare, the recommended approach for solitary lesions is gross total resection followed by adjuvant radiation. One series of eight patients found that those who did not develop myeloma in the early postoperative period remained disease-free over a mean follow-up of 12 years after complete resection and radiation. However, subtotal resection led to recurrence in one patient despite radiation, underscoring that incomplete removal is risky.17Journal of Neurosurgery. Management of intracranial plasmacytoma
Systemic Therapy and Emerging Approaches
Chemotherapy has traditionally played a limited role in solitary plasmacytoma because the disease, by definition, is localized. But as the high progression rates for bone plasmacytoma have become clearer, the logic of adding systemic treatment to radiation has gained traction. A 2025 review noted that adjuvant chemotherapy is gaining importance in treatment planning, with clinical trials underway.18PubMed Central. Solitary Plasmacytomas: Current Status in 2025 The goal is to eliminate minimal residual disease that local radiation cannot reach, particularly the tiny clonal populations hiding in the bone marrow.
When a plasmacytoma does progress or recur in disseminated form, treatment shifts to myeloma-type regimens. One published case of a patient who developed widespread cutaneous plasmacytomas a decade after an initial nasal SEP described treatment with a bortezomib-based combination, which achieved a complete response. The patient later relapsed but achieved a second remission on lenalidomide-based maintenance therapy.19PubMed Central. Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case This kind of long-delayed recurrence highlights why prolonged surveillance is considered essential.
Head and Neck Plasmacytomas
The head and neck region is the most common soft-tissue site for extramedullary plasmacytoma. Within that region, the nasal cavity and paranasal sinuses dominate, followed by the nasopharynx. In a systematic review of 315 head and neck cases, the median age was 57, the median tumor size was 3 cm, and radiation was used as part of treatment in about 78% of cases. Five-year local control exceeded 94%.20PubMed. Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases Risk factors for local relapse included sinonasal location, secretory tumors, and size exceeding 5 cm. Bony erosion and larger size were also associated with a higher risk of eventual myeloma relapse.
Treatment in this region often combines surgery and radiation. In a smaller series of 13 patients, about 69% had surgical resection followed by radiation, while 23% received radiation alone. After a median follow-up of 28 months, the vast majority remained alive and disease-free, though two patients had died of myeloma, reinforcing the importance of continued monitoring even when local control appears complete.21Journal of Oral Oncology. Head and Neck Solitary Extramedullary Plasmacytoma
Unusual Locations and Atypical Presentations
While bone and head-and-neck sites account for most cases, plasmacytomas can theoretically arise almost anywhere. Gastrointestinal involvement, though uncommon, has been documented. These tumors can present with bleeding (most often melena), mass effects, or organ dysfunction depending on where they sit. In a literature review of 27 gastrointestinal cases presenting with upper GI bleeding, the stomach was the most common site, followed by the duodenum. Most of these GI plasmacytomas turned out to be secondary manifestations of existing myeloma rather than true solitary tumors, which makes distinguishing primary from secondary disease clinically important.22PubMed Central. Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature
Primary cutaneous plasmacytoma is rarer still. There is intriguing evidence that chronic local stimulation may play a role: one case involved a lip plasmacytoma at a site that had been affected by recurrent herpes simplex infections for 15 years. The hypothesis is that persistent viral irritation of skin cells may have driven cytokine release that favored plasma cell survival and eventual malignant transformation.23Clinical and Experimental Dermatology. Primary cutaneous plasmacytoma: a role for a triggering stimulus?
Dural-based (brain-lining) plasmacytomas are among the rarest presentations. When they occur, they need to be distinguished carefully from solitary masses versus early manifestations of systemic myeloma. In one series, half of patients with intracranial plasmacytomas were found to have myeloma in the immediate postoperative period, and lesions near the skull base were especially likely to be associated with systemic disease rather than being truly solitary.24Journal of Neurosurgery. Management of intracranial plasmacytoma
Monitoring After Treatment
Because so many solitary plasmacytomas, particularly those in bone, eventually progress to myeloma, long-term surveillance is not optional. Monitoring typically includes periodic blood and urine protein studies, but imaging is increasingly recognized as valuable. One study found that among patients who progressed, post-treatment PET/CT had been positive in about two-thirds of cases, while only half had biochemical evidence of relapse at the time of clinical progression. That suggests imaging may catch progression earlier than blood tests alone.25Clinical Lymphoma, Myeloma and Leukemia. Solitary plasmacytomas are characterised by focal proliferation of monoclonal plasma cells in either soft tissue or bone
For patients who have completed radiation for bone plasmacytoma, early post-treatment PET/CT using a metabolic threshold (an SUVmax above 4) proved highly specific for identifying those at risk of progression, with one analysis showing roughly nine-fold higher risk of progression in PET-positive patients.26Clinical Nuclear Medicine. 18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas These findings are pushing the field toward incorporating functional imaging alongside traditional lab-based monitoring.
Molecular Clues and Tumor Biology
At the molecular level, plasmacytomas are revealing complexity that helps explain why some tumors behave aggressively while others remain indolent. Whole-exome sequencing of a case where a patient had both a bone plasmacytoma and an oral soft-tissue plasmacytoma showed shared mutations in genes like KRAS and PTPN13, confirming the two tumors were clonally related. But the soft-tissue lesion had acquired additional genetic hits, including an extra MYC translocation, suggesting it had evolved further toward aggressive behavior.27PubMed. Plasmablastic plasmacytoma followed by a plasmacytic plasma cell myeloma: insights into discordant extramedullary transformation-a case report and literature review
There are also differences at the protein level between the two main types. One immunohistochemistry study found that bone plasmacytoma cells expressed significantly higher levels of the adhesion molecule CD166 compared with extramedullary plasmacytoma cells, while extramedullary tumors had higher rates of cell proliferation as measured by Ki-67 staining, regardless of how the cells looked under the microscope.28BMC Cancer. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry This suggests the two types are not simply the same disease in different locations but may differ in fundamental biology, which could eventually lead to type-specific treatment strategies.
Plasmacytoma in Dogs
Plasmacytomas are not unique to humans. They are relatively well-recognized in veterinary oncology, particularly in dogs. Oral extramedullary plasmacytomas in dogs generally carry a favorable prognosis, with one 15-year study of 45 cases finding a median survival time of about 973 days after treatment. However, nearly a third of dogs in that cohort experienced progression of their plasma cell disease, including two cases with myeloma-like progression, mirroring the human concern about systemic spread.29PubMed. A retrospective study of canine oral extramedullary plasmacytoma over a 15-year period (July 2004-July 2019): Treatment, histologic parameters and clinical outcomes In rare instances, canine oral plasmacytomas have even metastasized to distant organs like the kidneys, an event documented with immunohistochemical confirmation that the kidney masses were plasma-cell derived.30PubMed Central. Extramedullary plasmacytoma of the oral cavity metastasising to both kidneys in a dog These veterinary parallels are useful because they provide additional biological models for understanding how a seemingly localized plasma-cell tumor can eventually go systemic.